Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Sales of Investments

Cash received from selling or redeeming investments.

Merck & Co., Inc.NYSE: MRK

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments growth accelerates

Q2 FY2026 sales of investments of $1.3B rose 116.8% year over year, ahead of the +72.7% change in trailing-twelve-month sales of investments. Over 3 fiscal years it compounded at +32.5% a year.

Context

  • Sales of investments amounted to 2.6% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +116.8% holds above the trailing-twelve-month pace of +72.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.3B— QoQ
Last fiscal yearDec 2025
$1.68B+345.1% YoY
LTMJun 2026
$1.92B+72.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+116.8%——
1 year+345.1%——
3-year CAGR+32.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
1.68B USD
Year-over-year change
+345.1%
4-year CAGR
+13.1%

Sales of Investments vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +72.7% is the 2nd highest of 8, against a peer median of -38.1%.
  • Sales of investments amounts to 2.9% of revenue for MRK, versus a peer median of 0.9%.
MRK Competitors
Sales of Investments for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$12.53B USD-38.1%-20.7%19.7%
MRKMerck & Co., Inc.LTM Jun 2026$1.92B USD+72.7%+32.5%2.9%
JNJJohnson & JohnsonLTM Sep 2026$1.41B USD-18.6%-65.8%1.4%
NVSNovartis AGLTM Jun 2026$1.19B USD-70.2%-61.9%2.1%
LLYEli Lilly and CompanyLTM Jun 2026$688.1M USD+45.5%+27.6%0.9%
GILDGilead Sciences, Inc.LTM Jun 2026$599M USD+93.2%-23.1%2.0%
SNYSanofiLTM Jun 2026€90.99M EUR——0.2%
ABBVAbbVie Inc.LTM Jun 2026$37M USD-93.7%-63.2%0.1%
AZNAstraZeneca PLCLTM Sep 2026$11.78M USD-86.9%+46.1%0.0%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding MRK) —-38.1%-23.1%0.9%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.36B14.53B365M17.13B18.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
Deferred Income Tax187M(1.57B)(1.9B)(1.25B)(1.67B)
Stock-Based Compensation479M541M645M761M0
Change in Working Capital(3.84B)(2.78B)(2.21B)(3.67B)(6.98B)
Accounts Receivables(2.03B)(644M)(1.15B)(244M)(1.09B)
Inventory(674M)(161M)(816M)(835M)(1.18B)
Accounts Payables405M(289M)(380M)182M110M
Other Working Capital(1.54B)(1.69B)139M(2.77B)(4.82B)
Other Non-Cash Items1.71B4.47B12.23B3.99B1.03B
Operating Cash Flow14.11B19.1B13.01B21.47B16.47B
Capital Expenditures(4.45B)(4.39B)(3.86B)(3.37B)(4.11B)
Acquisitions (Net)(12.91B)(121M)(12.03B)(4.09B)(10.04B)
Purchases of Investments(1M)(1.2B)(955M)(519M)(1.21B)
Sales of Investments1.03B721M1.66B377M1.68B
Other Investing Activities(225M)32M1.11B(127M)(58M)
Investing Cash Flow(16.56B)(4.96B)(14.08B)(7.73B)(13.74B)
Debt Repayment1.63B(2.25B)4.18B2.31B11.38B
Common Stock Issued0384M0092M
Common Stock Repurchased(840M)0(1.35B)(1.31B)(5.08B)
Dividends Paid(6.61B)(7.01B)(7.45B)(7.84B)(8.18B)
Other Financing Activities8.41B(240M)(203M)(195M)(131M)
Financing Cash Flow2.59B(9.12B)(4.81B)(7.03B)(1.92B)
Effect of Forex Changes(133M)(410M)23M(293M)563M
Net Change in Cash14M4.61B(5.86B)6.41B1.37B
Free Cash Flow9.66B14.71B9.14B18.1B12.36B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.